FBN2 and metastatic neoplasm: This is of importance because, in a recent study investigating the ccA/ccB signature [10], approximately one-quarter of metastatic tumors (two of nine patients) displayed intra-tumor heterogeneity and, in 43% of the cases, patient-matched primary and metastatic tumors displayed different molecular ccA/ccB subtypes.